TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 8.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 606,750 shares of the company’s stock after selling 59,536 shares during the quarter. Mackenzie Financial Corp’s holdings in TransMedics Group were worth $91,389,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Amalgamated Bank increased its stake in TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after buying an additional 70 shares during the period. Pitcairn Co. boosted its stake in TransMedics Group by 1.5% in the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after acquiring an additional 78 shares during the period. Signaturefd LLC grew its stake in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the last quarter. Arizona State Retirement System lifted its position in TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after purchasing an additional 186 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of TransMedics Group during the second quarter valued at approximately $47,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on TMDX. Piper Sandler boosted their price target on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Oppenheimer raised their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target for the company. Needham & Company LLC assumed coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 price objective on the stock. Finally, TD Cowen upped their target price on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $174.30.

Insider Transactions at TransMedics Group

In related news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. The disclosure for this sale can be found here. Insiders have sold a total of 61,247 shares of company stock valued at $9,650,880 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

TMDX opened at $159.14 on Friday. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The firm has a market cap of $5.24 billion, a PE ratio of -468.06 and a beta of 1.99. The business has a fifty day simple moving average of $156.02 and a 200-day simple moving average of $130.87. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter last year, the business posted ($0.03) EPS. TransMedics Group’s revenue was up 117.7% on a year-over-year basis. As a group, equities analysts predict that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.